0.15% Ketoconazole In Usp Trizedta

Verify with FDA CVM →

43 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
43
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

0.15% Ketoconazole In Usp Trizedta

Administration Routes

Auricular (Otic)Unknown

Species Affected

Dog 36
Cat 7

Most Affected Breeds

Retriever - Labrador 7
Retriever - Golden 5
Domestic Shorthair 4
American Pit Bull Terrier 3
Shepherd Dog - German 3
Maltese 2
Chihuahua 2
Siamese 2
Spaniel - King Charles 2
Spaniel (unspecified) 1

Most Reported Reactions

Loss of hearing 11
Head shake - ear disorder 6
Weight loss 5
Ear discharge 5
Ataxia 5
Decreased appetite 4
Third eyelid protrusion 4
Schirmer tear test 4
Deafness 4
Lethargy (see also Central nervous system depression in 'Neurological') 3
Decreased red blood cell count 3
Vomiting 3

Outcome Breakdown

Outcome Unknown
19 (44.2%)
Ongoing
11 (25.6%)
Recovered with Sequela
7 (16.3%)
Recovered/Normal
6 (14.0%)

Data Summary

Metric Value
Total adverse event reports 43
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

0.15% Ketoconazole In Usp Trizedta Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 43 adverse event reports referencing 0.15% Ketoconazole In Usp Trizedta, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: 0.15% Ketoconazole In Usp Trizedta. Reported administration routes include Auricular (Otic), Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in 0.15% Ketoconazole In Usp Trizedta reports are Dog (36 reports), Cat (7 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (7), Retriever - Golden (5), Domestic Shorthair (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with 0.15% Ketoconazole In Usp Trizedta are Loss of hearing (11), Head shake - ear disorder (6), Weight loss (5), Ear discharge (5). Of the 43 reports with a coded outcome, Outcome Unknown is the leading category at 44.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on 0.15% Ketoconazole In Usp Trizedta.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial